SIAE

Summary

SIAE (sialic acid acetylesterase, HGNC:18187) is a protein-coding gene on chromosome 11q24.2, encoding Sialate O-acetylesterase (Q9HAT2). Catalyzes the removal of O-acetyl ester groups from position 9 of the free diacetylated sialate N-acetyl-9-O-acetylneuraminate (Neu5,9Ac2) in the cytosol and of the diacetylated sialate residues of sialylglycoconjugates in the lysosomes.

This gene encodes an enzyme which removes 9-O-acetylation modifications from sialic acids. Mutations in this gene are associated with susceptibility to autoimmune disease 6. Multiple transcript variants encoding different isoforms, found either in the cytosol or in the lysosome, have been found for this gene.

Source: NCBI Gene 54414 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autoimmune disease, susceptibility to, 6 (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 558 total
• Druggable target: yes
• MANE Select transcript: NM_170601

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18187
Approved symbol	SIAE
Name	sialic acid acetylesterase
Location	11q24.2
Locus type	gene with protein product
Status	Approved
Aliases	CSE-C, MGC87009, LSE
Ensembl gene	ENSG00000110013
Ensembl biotype	protein_coding
OMIM	610079
Entrez	54414

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 6 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000263593, ENST00000436137, ENST00000525730, ENST00000533613, ENST00000545756, ENST00000618733, ENST00000899891, ENST00000899892, ENST00000947745

RefSeq mRNA: 2 — MANE Select: NM_170601 NM_001199922, NM_170601

CCDS: CCDS55795, CCDS8449

Canonical transcript exons

ENST00000263593 — 10 exons

Exon	Start	End
ENSE00001014285	124639710	124639867
ENSE00001014286	124648066	124648175
ENSE00001014287	124633113	124637202
ENSE00001014289	124638542	124638737
ENSE00001014293	124647365	124647498
ENSE00001014294	124649619	124649796
ENSE00001133647	124673642	124673739
ENSE00003512275	124654655	124654793
ENSE00003597209	124660628	124660803
ENSE00003631543	124669360	124669521

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 97.78.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.9142 / max 129.1825, expressed in 1776 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
122946	13.7215	1773
122947	0.1104	52
122944	0.0659	33
122945	0.0164	7

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of sigmoid colon	UBERON:0004993	97.78	gold quality
rectum	UBERON:0001052	97.77	gold quality
colonic mucosa	UBERON:0000317	97.73	gold quality
ileal mucosa	UBERON:0000331	97.19	gold quality
mucosa of transverse colon	UBERON:0004991	96.58	gold quality
left ventricle myocardium	UBERON:0006566	95.51	gold quality
kidney epithelium	UBERON:0004819	95.38	gold quality
heart right ventricle	UBERON:0002080	95.18	gold quality
heart left ventricle	UBERON:0002084	93.63	gold quality
cardiac ventricle	UBERON:0002082	93.59	gold quality
right atrium auricular region	UBERON:0006631	92.60	gold quality
cardiac atrium	UBERON:0002081	92.51	gold quality
adult mammalian kidney	UBERON:0000082	92.45	gold quality
cardiac muscle of right atrium	UBERON:0003379	92.42	gold quality
myocardium	UBERON:0002349	92.11	gold quality
transverse colon	UBERON:0001157	92.04	gold quality
apex of heart	UBERON:0002098	91.98	gold quality
heart	UBERON:0000948	91.72	gold quality
renal medulla	UBERON:0000362	91.60	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	91.19	gold quality
duodenum	UBERON:0002114	91.04	gold quality
thyroid gland	UBERON:0002046	90.82	gold quality
kidney	UBERON:0002113	90.71	gold quality
left lobe of thyroid gland	UBERON:0001120	90.67	gold quality
spinal cord	UBERON:0002240	90.59	gold quality
buccal mucosa cell	CL:0002336	90.52	gold quality
corpus epididymis	UBERON:0004359	90.43	gold quality
right lobe of thyroid gland	UBERON:0001119	90.27	gold quality
prefrontal cortex	UBERON:0000451	90.19	gold quality
islet of Langerhans	UBERON:0000006	90.02	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

54 targeting SIAE, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-8062	99.88	68.43	995
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-8061	99.63	69.44	1411
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-217-5P	99.49	69.93	1419
HSA-MIR-4688	99.48	64.68	828
HSA-MIR-6743-5P	99.48	63.60	721
HSA-MIR-6083	99.47	68.73	2393
HSA-MIR-20A-3P	99.44	69.10	1575
HSA-MIR-548AV-3P	99.43	68.50	1721
HSA-MIR-302A-5P	99.39	68.21	1913

Literature-anchored findings (GeneRIF, showing 11)

• odds ratio for inheriting defective SIAE alleles was 8.6 in all autoimmune subjects, 8.3 in subjects with rheumatoid arthritis, and 7.9 in subjects with type I diabetes (PMID:20555325)
• SIAE expression is upregulated in placentas from pregnancies complicated by preeclampsia. (PMID:21183218)
• Functionally defective germline variant of sialic acid acetylesterase (Met89Val) is not associated with type 1 diabetes mellitus and Graves’ disease. (PMID:21615338)
• These studies demonstrate that both SIAE and SOAT activities seem to be responsible for the enhanced level of Neu5,9Ac(2) in lymphoblasts, which is a hallmark in acute lymphoblastic leukemia (PMID:21803834)
• SIAE variants play a role in primary biliary cirrhosis. (PMID:22257840)
• There is no evidence for SIAE genetic variants affecting patients with vitiligo. (PMID:22913750)
• The analysis does not support a role for rare variants in SIAE in the pathogenesis of autoimmune Addison’s disease. (PMID:23011869)
• SIAE may be associated with autoimmunity. (PMID:23308225)
• We found A467V SIAE variants (c.1400C>T, rs7941523) in a heterozygous state in all the patients with anti-PIT-1 antibody syndrome. (PMID:24748456)
• Authors determined whether mutations in the SIAE gene are responsible for RA in a Han Chinese population (PMID:26535733)
• analysis of whether SIAE rare variants associated with phenotype of juvenile idiopathic arthritis (JIA) and autoimmunity risk in families with primary antibody deficiencies(PADS); 3 novel variants were found in patients with JIA and in their healthy relatives without autoimmunity; none of PAD patients or their relatives had SIAE defects; results show SIAE rare variants are not causative of autoimmunity as single defects (PMID:28900629)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	siae	ENSDARG00000040527
mus_musculus	Siae	ENSMUSG00000001942
rattus_norvegicus	Siae	ENSRNOG00000031266

Protein

Protein identifiers

Sialate O-acetylesterase — Q9HAT2 (reviewed: Q9HAT2)

Alternative names: H-Lse, Sialic acid-specific 9-O-acetylesterase

All UniProt accessions (1): Q9HAT2

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the removal of O-acetyl ester groups from position 9 of the free diacetylated sialate N-acetyl-9-O-acetylneuraminate (Neu5,9Ac2) in the cytosol and of the diacetylated sialate residues of sialylglycoconjugates in the lysosomes. Together with the sialate-O-acetyltransferase they regulate the balance of acetylated sialoglycoconjugates, key players in various processes such as cell-cell interactions, host-pathogen recognition, and tumor antigenicity.

Subcellular location. Lysosome Cytoplasm.

Tissue specificity. Widely expressed with high expression in the testis, prostate, and colon.

Disease relevance. Autoimmune disease 6 (AIS6) [MIM:613551] Individuals manifesting susceptibility to autoimmune disease type 6 can suffer from juvenile idiopathic arthritis, rheumatoid arthritis, multiple sclerosis, Sjogren syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, and Crohn disease. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9HAT2-1	1	yes
Q9HAT2-2	2

RefSeq proteins (2): NP_001186851, NP_733746* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005181	SASA	Domain
IPR036514	SGNH_hydro_sf	Homologous_superfamily
IPR039329	SIAE	Family

Pfam: PF03629

Enzyme classification (BRENDA):

• EC 3.1.1.53 — sialate O-acetylesterase (BRENDA: 40 organisms, 142 substrates, 52 inhibitors, 19 Km, 3 kcat entries)

Substrate kinetics (BRENDA)

10 substrates with measured Km, best-characterized 10. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
N-ACETYL-9-O-ACETYLNEURAMINIC ACID	0.8–18	4
4-NITROPHENYL ACETATE	0.0512–0.129	2
4-YETHYLUMBELLIFERYL ACETATE	0.13–0.17	2
9-O-ACETYL-SIALIC ACID	1.1–1.3	2
N-ACETYL-9-O-LACTOYLNEURAMINIC ACID	0.9–24	2
4-O-ACETYL-SIALIC ACID	0.3	1
ACETYL-COA	1.28	1
ALACEPRIL	22	1
ALPHA-NAPHTHYL ACETATE	1.71	1
SPIRONOLACTONE	0.652	1

Catalyzed reactions (Rhea), 2 shown:

• N-acetyl-9-O-acetylneuraminate + H2O = N-acetylneuraminate + acetate + H(+) (RHEA:22600)
• an Ac-O-9-sialoglycoconjugate + H2O = a sialoglycoconjugate + acetate + H(+) (RHEA:80763)

UniProt features (32 total): sequence variant 23, glycosylation site 6, signal peptide 1, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HAT2-F1	92.26	0.87

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (6): 107, 138, 267, 290, 401, 422

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 124 (showing top): SHEPARD_BMYB_MORPHOLINO_UP, SP3_Q3, GGGTGGRR_PAX4_03, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, TGGAAA_NFAT_Q4_01, MARSON_BOUND_BY_FOXP3_STIMULATED, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS, MATSUDA_NATURAL_KILLER_DIFFERENTIATION, chr11q24, GOMF_CARBOXYLIC_ESTER_HYDROLASE_ACTIVITY

GO Biological Process (2): regulation of immune system process (GO:0002682), carbohydrate metabolic process (GO:0005975)

GO Molecular Function (5): sialate O-acetylesterase activity (GO:0001681), sialate 9-O-acetylesterase activity (GO:0106330), protein binding (GO:0005515), hydrolase activity (GO:0016787), carboxylic ester hydrolase activity (GO:0052689)

GO Cellular Component (4): obsolete extracellular space (GO:0005615), lysosome (GO:0005764), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
immune system process	1
regulation of biological process	1
primary metabolic process	1
acetylesterase activity	1
sialate O-acetylesterase activity	1
binding	1
catalytic activity	1
hydrolase activity, acting on ester bonds	1
lytic vacuole	1
extracellular vesicle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

682 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SIAE	CASD1	Q96PB1	796
SIAE	CD22	P20273	728
SIAE	SLC2A1	P11166	685
SIAE	NANS	Q9NR45	591
SIAE	ABHD2	P08910	519
SIAE	SLC35A1	P78382	512
SIAE	NPIPB4	C9JG80	507
SIAE	CES5A	Q6NT32	507
SIAE	ST3GAL5	Q9UNP4	506
SIAE	ST3GAL2	Q16842	492
SIAE	TMEM242	Q9NWH2	490
SIAE	LYN	P07948	484
SIAE	SIGLEC15	Q6ZMC9	463
SIAE	PLBD2	Q8NHP8	457
SIAE	ZNF280C	Q8ND82	450

IntAct

10 interactions, top by confidence:

A	B	Type	Score
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
SIAE	FBXO2	psi-mi:“MI:0915”(physical association)	0.500
SIAE	NPTX1	psi-mi:“MI:0915”(physical association)	0.400
	VPS37C	psi-mi:“MI:0914”(association)	0.350
DEFB109B	CHST10	psi-mi:“MI:0914”(association)	0.350
EDDM3A	PLXNA2	psi-mi:“MI:0914”(association)	0.350
SIAE	NPTXR	psi-mi:“MI:0914”(association)	0.350
CLGN	TMEM131L	psi-mi:“MI:0914”(association)	0.350
EPHA1	SIAE	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (94): SIAE (Affinity Capture-MS), CPE (Affinity Capture-MS), HLA-B (Affinity Capture-MS), ENTPD6 (Affinity Capture-MS), NPTX1 (Affinity Capture-MS), CNTNAP3 (Affinity Capture-MS), MANEAL (Affinity Capture-MS), OAF (Affinity Capture-MS), TMEM30A (Affinity Capture-MS), MR1 (Affinity Capture-MS), COCH (Affinity Capture-MS), FAM162A (Affinity Capture-MS), GPR98 (Affinity Capture-MS), GFPT2 (Affinity Capture-MS), MOXD1 (Affinity Capture-MS)

ESM2 similar proteins: A0JMP0, A4IG42, A5PJN5, A6QLU7, A6QQ07, F1N2K1, O00462, O18835, O43280, O77695, O95479, O97524, P08236, P10253, P12265, P19813, P70699, P82450, Q3U4H6, Q4FAT7, Q4FZV0, Q5E985, Q5FVF9, Q5R5N6, Q5R7A9, Q5R8R3, Q5RFU0, Q5XHI4, Q641Z7, Q6P6V7, Q6P7A9, Q6QR59, Q6RHW4, Q76HN1, Q865R1, Q8BFW6, Q8BNE1, Q8BP56, Q8C0L6, Q8CFX1

Diamond homologs: P70665, P82450, Q5RFU0, Q9HAT2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

558 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	348
Likely benign	166
Benign	22

Top pathogenic / likely-pathogenic (0)

SpliceAI

2225 predictions. Top by Δscore:

Variant	Effect	Δscore
11:124638738:C:CC	acceptor_gain	1.0000
11:124654650:CATA:C	donor_loss	1.0000
11:124654651:ATACC:A	donor_loss	1.0000
11:124654652:TACCT:T	donor_loss	1.0000
11:124654653:ACCT:A	donor_loss	1.0000
11:124654654:C:A	donor_loss	1.0000
11:124654791:TAT:T	acceptor_gain	1.0000
11:124654791:TATC:T	acceptor_loss	1.0000
11:124654792:ATCT:A	acceptor_loss	1.0000
11:124654793:TCTG:T	acceptor_loss	1.0000
11:124654794:C:CG	acceptor_loss	1.0000
11:124654795:T:A	acceptor_loss	1.0000
11:124669354:CCTTA:C	donor_loss	1.0000
11:124669355:CTTA:C	donor_loss	1.0000
11:124669356:TTA:T	donor_loss	1.0000
11:124669357:TACC:T	donor_loss	1.0000
11:124669358:ACCTT:A	donor_loss	1.0000
11:124669359:C:CG	donor_loss	1.0000
11:124673950:G:GT	donor_gain	1.0000
11:124675415:GAGA:G	donor_gain	1.0000
11:124675417:GA:G	donor_gain	1.0000
11:124675419:G:GG	donor_gain	1.0000
11:124691686:A:AG	acceptor_gain	1.0000
11:124691687:T:G	acceptor_gain	1.0000
11:124691689:T:TA	acceptor_gain	1.0000
11:124691691:TCCA:T	acceptor_loss	1.0000
11:124691694:A:AG	acceptor_gain	1.0000
11:124691694:AG:A	acceptor_gain	1.0000
11:124691694:AGG:A	acceptor_loss	1.0000
11:124691695:G:GG	acceptor_gain	1.0000

AlphaMissense

3428 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:124660672:A:G	W121R	0.990
11:124660672:A:T	W121R	0.990
11:124647429:C:G	R301P	0.987
11:124637087:C:G	R479P	0.986
11:124647433:A:G	W300R	0.981
11:124647433:A:T	W300R	0.981
11:124660661:A:C	S124R	0.981
11:124660661:A:T	S124R	0.981
11:124660663:T:G	S124R	0.981
11:124638699:A:G	L388P	0.980
11:124639741:C:G	D365H	0.980
11:124638719:T:A	K381N	0.978
11:124638719:T:G	K381N	0.978
11:124648075:A:G	W275R	0.977
11:124648075:A:T	W275R	0.977
11:124638702:C:G	R387P	0.976
11:124638720:T:A	K381I	0.976
11:124649665:A:G	W226R	0.976
11:124649665:A:T	W226R	0.976
11:124654673:A:G	W176R	0.976
11:124654673:A:T	W176R	0.976
11:124660664:A:C	C123W	0.974
11:124649752:A:G	W197R	0.971
11:124649752:A:T	W197R	0.971
11:124649733:A:G	L203P	0.970
11:124639740:T:G	D365A	0.969
11:124649703:A:G	L213P	0.968
11:124649753:G:C	C196W	0.968
11:124660666:A:G	C123R	0.966
11:124649663:C:A	W226C	0.965

dbSNP variants (sampled 300 via entrez): RS1000151876 (11:124634220 G>A), RS1000178570 (11:124656153 C>A), RS1000215927 (11:124675064 T>G), RS1000272722 (11:124674841 A>T), RS1000334970 (11:124637321 A>G), RS1000340572 (11:124643065 T>C), RS1000358431 (11:124645323 T>C), RS1000464609 (11:124658360 AT>A), RS1000556280 (11:124663832 C>A), RS1000669766 (11:124648476 G>A), RS1000719933 (11:124632927 C>G), RS1000789767 (11:124642098 A>T), RS1000978218 (11:124661692 A>G), RS1000982215 (11:124662005 T>A), RS1001209800 (11:124666753 G>A)

Disease associations

OMIM: gene MIM:610079 | disease phenotypes: MIM:613551, MIM:604302

GenCC curated gene-disease

Disease	Classification	Inheritance
autoimmune disease, susceptibility to, 6	Limited	Unknown

Mondo (2): autoimmune disease, susceptibility to, 6 (MONDO:0013303), juvenile idiopathic arthritis (MONDO:0011429)

Orphanet (1): Juvenile idiopathic arthritis (Orphanet:92)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002388_11	Serum metabolite levels	5.000000e-14
GCST006865_13	Bipolar disorder	6.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001171	Arthritis, Juvenile	C05.550.114.122; C05.799.056; C17.300.775.049; C20.111.198

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523459 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	6
aristolochic acid I	decreases expression	1
bisphenol F	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenate	decreases expression, increases abundance	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
manganese chloride	increases abundance, increases expression	1
ochratoxin A	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	increases reaction, affects binding	1
nutlin 3	affects cotreatment, increases secretion	1
belinostat	increases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression	1
Arsenic	increases abundance, decreases expression	1
Cadmium	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases secretion	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Ivermectin	decreases expression	1
Manganese	increases abundance, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4335411	Binding	Binding affinity to SIAE in human Huh7.5.1 cell lysate infected with HCV at 0.1 to 10 uM incubated for 1 hr followed by 10000 mJ/cm2 UV irradiation for 10 mins and subsequent addition of biotin-N3 measured after 1 hr by ABPP Gel-based by LC	Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors. — J Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TL07	HAP1 SIAE (-) 1	Cancer cell line	Male
CVCL_TL08	HAP1 SIAE (-) 2	Cancer cell line	Male
CVCL_TL09	HAP1 SIAE (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

230 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00443430	PHASE4	COMPLETED	Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
NCT00637780	PHASE4	TERMINATED	Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
NCT00731965	PHASE4	COMPLETED	Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis
NCT00792233	PHASE4	COMPLETED	Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
NCT00807846	PHASE4	COMPLETED	A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
NCT00815282	PHASE4	COMPLETED	Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
NCT01151644	PHASE4	UNKNOWN	Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases
NCT01287715	PHASE4	UNKNOWN	Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis
NCT01544114	PHASE4	COMPLETED	A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
NCT01563185	PHASE4	COMPLETED	Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
NCT01734382	PHASE4	COMPLETED	A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
NCT02024334	PHASE4	UNKNOWN	Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis
NCT02196480	PHASE4	COMPLETED	23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy
NCT03069638	PHASE4	COMPLETED	Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population
NCT03301883	PHASE4	COMPLETED	A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT03816397	PHASE4	COMPLETED	Adalimumab in JIA-associated Uveitis Stopping Trial
NCT04614311	PHASE4	COMPLETED	Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA).
NCT04687930	PHASE4	COMPLETED	Genicular Nerve Block in Juvenile Idiopathic Arthritis
NCT05879419	PHASE4	ACTIVE_NOT_RECRUITING	Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
NCT06618937	PHASE4	NOT_YET_RECRUITING	Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission
NCT06653634	PHASE4	RECRUITING	Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial
NCT07087912	PHASE4	RECRUITING	Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
NCT07428551	PHASE4	COMPLETED	Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients
NCT00012506	PHASE3	UNKNOWN	The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis
NCT00034853	PHASE3	COMPLETED	Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)
NCT00078806	PHASE3	TERMINATED	Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis
NCT00095173	PHASE3	COMPLETED	BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
NCT00279747	PHASE3	COMPLETED	A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)
NCT00420251	PHASE3	COMPLETED	Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis
NCT00570934	PHASE3	COMPLETED	Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA
NCT00642460	PHASE3	COMPLETED	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
NCT00652925	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
NCT00690573	PHASE3	COMPLETED	Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis
NCT00775437	PHASE3	COMPLETED	Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
NCT00988221	PHASE3	COMPLETED	A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
NCT01015547	PHASE3	COMPLETED	Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis
NCT01230827	PHASE3	TERMINATED	A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
NCT01541917	PHASE3	COMPLETED	Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis
NCT01575769	PHASE3	TERMINATED	An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis
NCT01667471	PHASE3	COMPLETED	A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study